CVRX
$8.33
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
Intraday
Recent News
CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ...
CVRx Inc (CVRX) reports increased revenue and expanded sales territories, while navigating financial hurdles and strategic transitions.
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
There's been a major selloff in CVRx, Inc. ( NASDAQ:CVRX ) shares in the week since it released its full-year report...
CVRx, Inc. Q4 2025 Earnings Call Summary
Moby summary of CVRx, Inc.'s Q4 2025 earnings call
CVRx Q4 Earnings Call Highlights
CVRx (NASDAQ:CVRX) reported fourth-quarter revenue of $16.0 million and full-year revenue of $56.7 million, representing growth of 4% and 10%, respectively, as the company continued investing in its commercial organization and initiatives aimed at expanding adoption of its Barostim therapy for heart
CVRx: Q4 Earnings Snapshot
The Minneapolis-based company said it had a loss of 46 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.